|
Post by tatshensini on Jan 26, 2017 0:48:31 GMT
Also found 36 videos on CRISPR and dCas9 and its applicable uses...here on VIMEO, through the Institute of Genomic Sciences.... Jennifer Doudna is the Executive Director for this organization. vimeo.com/igisci/videos
|
|
|
Post by iamaverb on Feb 2, 2017 10:02:12 GMT
|
|
|
Post by iamaverb on Feb 4, 2017 5:03:44 GMT
How A 2015 Trial Sheds Light On The CRISPR Patent Case "As has been written about—at length—elsewhere, much of the biotech world awaits the outcome of a patent dispute over CRISPR, a revolutionary form of gene-editing biotechnology worth many billions of dollars." I met the author of this article at the patent hearing in DC early December, and I have built my investment strategy around what he told me then, and what he wrote a day ago. This is an important read for any serious investor. For important notifications on breaking news on CRISPR, go to the CRISPRINVESTOR fb page and click to follow the page. You will get real time updates sent to your phone and computer. When this case is settled by the 3 Judge panel, I will be posting the outcome there first. Facebook/CRISPR/INVESTOR
|
|
|
Post by iamaverb on Feb 14, 2017 15:28:56 GMT
The recent filings of the SEC's 13G/a forms show a large uptick in big investors in the CRISPR space, with some notable hedge funds taking sizeable positions in CRSP and EDIT in 4Q 2016. I suppose you could say they are placing their bets before the next hand is dealt. As an observation, yesterday was the first time ever that CRSP had more volume than EDIT.
|
|
|
Post by iamaverb on Feb 15, 2017 17:45:38 GMT
At 11:43 central something just rocketed EDIT up 18% in 2 minutes. Go to fb/ CRISPR Investor for direct notifications.
|
|
|
Post by selluwud on Feb 15, 2017 19:15:29 GMT
|
|
|
Post by iamaverb on Feb 15, 2017 19:20:42 GMT
Within 15 minutes of the news coming out on the USPTO website at 11:43 central, I sold 80% of my oil stocks plowed it into EDIT. This is far from over. Booyah!! Remember to follow my fb page CRISPR INVESTOR to get immediate updates on breaking news sent to your phone or computer. edit: This EDIT by the numbers. Up today 29% & $5.44 with 18 x daily volume. Short interest was up 33% over the month before and represents 14.6% of the shares, close to 40% of today's volume. I feel a short squeeze is underway. Jefferies, BEFORE the decision was made, gave a price target of $35.00. Hope others did as well as I did today because of my due diligence.
|
|
|
Post by actcfan on Feb 15, 2017 21:13:25 GMT
Congrats to holders. Thanks iamverb for keeping us informed.
I was very lucky to double my small position here on Monday.
|
|
|
Post by actcfan on Feb 15, 2017 21:19:40 GMT
How A 2015 Trial Sheds Light On The CRISPR Patent Case "As has been written about—at length—elsewhere, much of the biotech world awaits the outcome of a patent dispute over CRISPR, a revolutionary form of gene-editing biotechnology worth many billions of dollars." I met the author of this article at the patent hearing in DC early December, and I have built my investment strategy around what he told me then, and what he wrote a day ago. This is an important read for any serious investor. For important notifications on breaking news on CRISPR, go to the CRISPRINVESTOR fb page and click to follow the page. You will get real time updates sent to your phone and computer. When this case is settled by the 3 Judge panel, I will be posting the outcome there first. Facebook/CRISPR/INVESTOR Reading this article Monday is why I bought more EDIT. Thanks again iamaverb, and thanks Jham for providing this community.
|
|
cruss
New Member
Posts: 4
|
Post by cruss on Feb 15, 2017 21:49:30 GMT
Thank you Iamaverb.
|
|
|
Post by nateb on Feb 15, 2017 21:59:20 GMT
Wow glad I bought more this morning before the move.
|
|
|
Post by iamaverb on Feb 15, 2017 22:33:19 GMT
Wow glad I bought more this morning before the move. And I believe the move is far from over. After the Hedge funds realize the risk has passed and begin to crunch the numbers, I see, at a minimum, EDIT reaching again it's all time high in the mid $30.00's. And then when the breakthroughs begin with this science, we might have another REGN Plus on our hands.
|
|
|
Post by tatshensini on Feb 16, 2017 1:00:55 GMT
I had bought a little earlier than I could have, took the risk with 15k shares...now excited for the science and licensing to move forward. I think this may be more of a licensing play, but the areas of licensing go far beyond the human body. So congrats to all who shared the vision.
|
|
|
Post by iamaverb on Feb 16, 2017 17:19:12 GMT
I had bought a little earlier than I could have, took the risk with 15k shares...now excited for the science and licensing to move forward. I think this may be more of a licensing play, but the areas of licensing go far beyond the human body. So congrats to all who shared the vision. Good job!. This patent case was concerning the particular gene editing tool of Cas9 to cleave the DNA, but EDIT has improved upon this with multiple patents covering the new Cpf1 cleaving tool, which is apparently more exact. CRISPR-Cpf1 Editing ToolA team from the Center for Genome Engineering, within the Institute for Basic Research (IBS), succeeded in editing two genes that contribute to the fat contents of soybean oil using the new CRISPR-Cpf1 technology: an alternative of the more widely used gene editing tool CRISPR-Cas9. The results of this new plant gene editing method, applied to soybeans and wild tobacco genes, are published in Nature Communications.
|
|
|
Post by RLC on Feb 16, 2017 19:03:05 GMT
I had bought a little earlier than I could have, took the risk with 15k shares...now excited for the science and licensing to move forward. I think this may be more of a licensing play, but the areas of licensing go far beyond the human body. So congrats to all who shared the vision. Good job!. This patent case was concerning the particular gene editing tool of Cas9 to cleave the DNA, but EDIT has improved upon this with multiple patents covering the new Cpf1 cleaving tool, which is apparently more exact. CRISPR-Cpf1 Editing ToolA team from the Center for Genome Engineering, within the Institute for Basic Research (IBS), succeeded in editing two genes that contribute to the fat contents of soybean oil using the new CRISPR-Cpf1 technology: an alternative of the more widely used gene editing tool CRISPR-Cas9. The results of this new plant gene editing method, applied to soybeans and wild tobacco genes, are published in Nature Communications. Thanks for posting all the DD iamverb! I had been following this thread but never made a move (unfortunately). After doing some reading last night I grabbed some $30 Aug call options this morning and am already up 15%+! As of right now I'm planning on selling fairly soon (I really need to get better at locking in profit when it's there). Thanks again man!
|
|
|
Post by iamaverb on Feb 17, 2017 14:46:04 GMT
Here is the UC Berkeley,CRSP/NTLA side of the patent outcome 2 days ago. This perhaps explains why the market reacted favorably to these two companies yesterday after they held their conference call.
The PTAB discontinued the current interference finding that the claim sets presented by the two parties were considered “patentably distinct” from each other because UC’s current claims are broader in scope in that they are not restricted to use in eukaryotic cells, whereas Broad’s claims are all limited to use in eukaryotic cells. As a result of the decision, UC’s broader case, which was previously considered allowable but for the interference, is now released from the interference and may be prosecuted to potential issuance by UC, while a new interference can be sought with respect to eukaryote claims, currently pending in a separate UC patent application once they are deemed allowable.
Editas will have a chance to present their side of outcome and during a company presentation next week at:
RBC Capital Markets 2017 Global Healthcare Conference Date / Time 02/22/17 10:30 a.m. ET Location New York
|
|
|
Post by iamaverb on Feb 18, 2017 17:56:56 GMT
Surgery with CRISPR-Cas9 may prevent blindnessThis may be deja vu all over again, but there are several studies underway working with the CRISPR gene editing tool on different forms of blindness. ACTC/OCAT was once the leader in the field, but ran out of money and ran up against opposition to using human embryonic stem cells here in the US to cure macular degeneration. Seoul, Feb 17 (IANS) Researchers have found that gene editing tool CRISPR-Cas9 can be delivered directly into the eye to treat age-related macular degeneration (AMD), an advance that may pave way for a new therapy for non-hereditary degenerative diseases. Now I will be the first to admit that the Koreans are known for their hyperbole, but this one treatment alone, if proved successful, could lead to billions.
|
|
|
Post by iamaverb on Feb 21, 2017 14:04:16 GMT
Just the tip of the iceberg, in my opinion. An article by the Intellectual Property Law Professor I met at the hearing. FYI: Since Wednesday, beginning minutes after the judgement was rendered, I more than doubled my position. How much are the CRISPR Patents Worth?
|
|
|
Post by actcfan on Feb 22, 2017 19:36:39 GMT
Not seeing any news, just profit taking for short term holders?
|
|
|
Post by RLC on Feb 22, 2017 20:07:22 GMT
Not seeing any news, just profit taking for short term holders? Wow I have no idea. I got ridiculously lucky this morning (nice to see it can go the other way!) and sold my options at the open to lock in a modest gain and pickup some more ONCS under $1.50. I couldn't find any news though so I would assume a large holder is taking some off the table after the move over the past week. I'm going to keep a close eye on this and will likely grab some more option contracts in the near future.
|
|